Amryt plans for series of agreements after an exclusive in-licence deal for a novel gene therapy platform, potentially exciting treatment for Epidermolysis bullosa

Joe Wiley, CEO of Amryt, said Amryt has an ambitious plans for the remainder of 2018 as it looks forward to announce a series of agreements in the months to come.

He said that this is a pivotal year for Amryt and the company’s focus will continue to be on ensuring that it is delivering real change for people with rare diseases across the world. “I am proud to say we are delivering on our promise,” Wiley said.

2017 was a very strong year for Amryt, the company’s CEO said in the press release pointing out good start of 2018. He said that the first period of the year gives the company a good position to be able to drive further expansion in the years to come.

As he’s proud with the growth of Lojuxta business since in-licensing it in December 2016, he noted that with the recent distribution agreements throughout Europe and the Middle-East, Amryt can now reach more people living with the ultra-rare and life-threatening condition, HoFH.

Based on these data from Amicus Therapeutics’s ESSENCE study in Epidermolysis bullosa (EB), Amryt now has the opportunity to refine its ongoing global Phase III EASE study of AP101 in EB, with the potential to increase the probability of success for the study. “We are truly grateful to Amicus Therapeutics for the opportunity, which is a heartening example of collaboration in our industry in the best interests of patients.” said Wiley.

Commenting specifically on the new in-licence agreement signed on March 14, 2018 with University College Dublin for exciting non-viral gene therapy platform technology, which offers a potential treatment for patients with EB Wiley, CEO of Amryt, said this is a great opportunity for to get involved in the area of gene therapy. Wiley said that it is one of the most exciting and potentially transformative areas of medicine today. He explained that gene therapy has come of age in the last number of years and is being applied to multiple orphan therapeutic areas.

“The HPAE polymer technology gives us a potential platform technology, with an initial topical application in EB, that does not rely on the use of viral vectors for the delivery of gene therapy,” Wiley said.

Amryt plans to continue to seek to in-license

He furhter noted that, if successful, this platform has the potential to be broadly applicable in other dermatological conditions and possibly beyond. In the meantime, Amryt plans to continue to seek to in-license further commercial stage assets. That will enable it to continue with the growth of revenues and provide cash resources that will help support these development assets, the company’s CEO said.

Wiley concluded: “Amryt now has in place an exceptionally strong leadership team with the necessary commercial, regulatory and medical infrastructure also in place in Europe.  Our strategy is to leverage this capacity to in-license more commercial stage assets, which we are actively pursuing.”